
Patients treated with the probiotic saw benefits in non-motor symptoms such as sleep, fatigue, and gastrointestinal outcomes.









Patients treated with the probiotic saw benefits in non-motor symptoms such as sleep, fatigue, and gastrointestinal outcomes.

After a year of treatment, patients showed significant improvements in ON time without troublesome dyskinesia, with more apparent effects observed in the high-dose group.

Lixisenatide, commonly used to treat type 2 diabetes, has the ability to cross the blood brain barrier and has shown neuroprotective properties in preclinical models of PD.

Danielle Kipnis, MA, of Columbia University, discussed the practice of yoga for people with functional neurological disorders from her research and recommendations for future studies in the field.

A study presented at the MDS Congress 2022 found an association between migraine and the incidence of Parkinson disease in the middle-aged and older population.

Results from a pooled analysis extend and support the safety and the tolerability of the use of incobotulinumtoxinA for the treatment of adults with neurological disorders.

One of the identified loci related to clinical progression in Parkinson disease expresses ADORA2A in the cerebellum, which encodes the adenosine A2A receptor, a promising target for therapeutics in PD.

The Parkinson disease agent showed a safe and tolerable profile, with significantly greater improvements in MDS-UPDRS-III scores and OFF time per day.

Danielle Kipnis, MA, of Columbia University, discussed key components of a yoga program for individuals with functional neurological disorder and from the evaluation, found it feasibility as an intervention.

Over a 2-year period, patients demonstrated improvements in Parkinson’s Disease Questionnaire scores, along with a 35% improvement in MDS-UPDRS-III scores.

The expert medical director at Roche provided detail on results from the phase 2 PASADENA study presented at the 2021 MDS Virtual Congress. [WATCH TIME: 3 minutes]

David R. Lynch, MD, PhD, professor of neurology, University of Pennsylvania Perelman School of Medicine, discussed why omaveloxolone’s recent success speaks to the progress made within the FA treatment space.

When used for at least 30 days, it was reported that patients with essential tremor reported improvement in tremor power following 54% of sessions.

The professor of neurology at the University of Pennsylvania Perelman School of Medicine discussed the state of care for Friedrich ataxia and omaveloxolone’s potential to become its first approved therapy.

Following her presentation at MDS 2021, the PhD candidate in epidemiology at Erasmus University Medical Center discussed highlights from this year’s virtual congress. [WATCH TIME: 2 minutes]

The professor of neurology at the University of Pennsylvania Perelman School of Medicine discussed whether omaveloxolone’s therapeutic benefit is enough for it to become the first approved therapy for Friedrich ataxia. [WATCH TIME: 2 minutes]

The PhD candidate in the epidemiology department at Erasmus University Medical Center in the Netherlands discussed the need for tailored treatment in light of the COVID-19 pandemic. [WATCH TIME: 4 minutes]

Following MDS 2021, we compiled a roundup of some of our discussions with experts in the Parkinson disease and movement disorders space in one convenient location.

The PhD candidate in the epidemiology department at Erasmus University Medical Center in the Netherlands discussed the need for tailored treatment in light of the COVID-19 pandemic. [WATCH TIME: 4 minutes]

The director of the UAB Huntington's Disease Clinic offered his insight on a recent assessment of HD genetic testing at HDSA Centers of Excellence, and the associated costs for patients.

The professor of neurology at the University of Pennsylvania Perelman School of Medicine discussed his presentation at MDS 2021, which highlighted the therapeutic benefit of omaveloxolone in Friedreich ataxia. [WATCH TIME: 2 minutes]

Data suggest that certain activities of daily living are more prevalent depending on whether the caregiver is a man or a woman.

Helen Colquhoun, MD, vice president of early development at Sage Therapeutics, commented on results from a phase 2 study in which patients receiving SAGE-324 showed a significant decrease in ET.

When asked about developments, the neurologist and movement disorders specialist at Sheba Tel-HaShomer Medical Center in Israel commented on the need to identify disease-modifying therapies. [WATCH TIME: 3 minutes]

Data were collected from the MDS’s membership worldwide, assessing current practices, concerns, and barriers to genetic testing.

Data found that synchronic dance classes conducted through Zoom may be particularly effective for patients who live remotely.

Following his presentation at the MDS Society Virtual Congress 2021, the neurologist and movement disorders specialist at Sheba Tel-HaShomer Medical Center discussed his views on the use of medical cannabis. [WATCH TIME: 3 minutes]

Patients were evaluated at day 29 for change in TETRAS item 4 score change from baseline.

Next steps for medical cannabis will need to include how cannabinoids affect the brain, according to the neurologist and movement disorders specialist at Sheba Tel-HaShomer Medical Center in Israel.

A study from the International Parkinson and Movement Disorder Society Virtual Congress suggest that despite protocol adherence, average costs are moderately high and vary significantly.